Manfred Windisch

Manfred Windisch is CEO of NSC-Therapeutics, a drug development company he founded in 2017, specialized in drug development for neurodegenerative disorders like Alzheimer’s disease, with a focus on highly specific muscarinic M1 agonists. He earned his PhD degree in Physiology and Biochemistry from the University of Graz, Austria, 1985. He spent several years heading a neurobiology group at the university with research in the field of brain metabolism and animal model development. He was involved for many years in research programs in Europe, North America, and Asia. He established a global network of research collaborations and stimulated scientific information exchange. 1999, he founded JSW-Lifesciences where he created transgenic and induced rodent models of neurodegenerative diseases and used these models in 60–80 pharmacological studies each year, allowing to define experimental standards to increase predictive value in preclinical drug testing. He initiated a clinical research gro